DySIS Medical Ltd (DySIS or the Company): National Institute for Clinical Excellence (NICE) Publishes Positive Diagnostics Guidance on DySIS Cervical Cancer Screening Product

Published: Aug 01, 2012

EDINBURGH, Scotland--(BUSINESS WIRE)--DySIS Medical Ltd, the medical devices company in female health, announces that the National Institute for Health and Clinical Excellence (‘NICE’) has today published positive diagnostics guidance recommending its DySIS cervical cancer screening product to be considered in procurement plans. DySIS colposcopy uses spectral imaging techniques during the course of a normal examination to highlight to clinicians any areas of concern by mapping the condition of a woman’s cervix. The DySISmap uses a range of colours to indicate normal and abnormal cells, and the degree of abnormality present.

Back to news